Cohort profile: the Nigerian HIV geriatric cohort study.
Elderly
Geriatric
HIV/AIDS
Nigeria
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
26 Nov 2020
26 Nov 2020
Historique:
received:
03
12
2019
accepted:
04
11
2020
entrez:
27
11
2020
pubmed:
28
11
2020
medline:
9
3
2021
Statut:
epublish
Résumé
The Nigerian HIV Geriatric Cohort (NHGC) is a longitudinal cohort setup to learn how elderly people living with HIV (EPLHIV) in Nigeria fare, despite not being prioritized by the national treatment program, and to deepen knowledge for their differentiated care and achieve better outcomes. In this paper, we describe data collected on sociodemographic and clinical data from EPLHIV from the inception of Nigeria's national HIV program to 2018. Patient-level data spanning the period 2004 to 2018, obtained from comprehensive HIV treatment hospitals, that are supported by four major PEPFAR-implementing partners in Nigeria were used. These 4 entities collaborated as member organizations of the Nigeria Implementation Science Alliance. We defined elderly as those aged 50 years and above. From deidentified treatment records, demographic and clinical data of EPLHIV ≥50-year-old at ART initiation during the review period was extracted, merged into a single REDcap® database, and described using STATA 13. A total of 101,652 EPLHIV were analysed. Women accounted for 53,608 (53%), 51,037 (71%) of EPLHIV identified as married and 33,446 (51%) unemployed. Median age was 57.1 years (IQR 52-60 years) with a median duration on ART treatment of 4.1 years (IQR 1.7-7.1 years). ART profile showed that 97,586 (96%) were on 1st-line and 66,125 (65%) were on TDF-based regimens. Median body mass index (BMI) was 22.2 kg/m This cohort describes the clinical and non-clinical profile of EPLHIV in Nigeria. We are following up the cohort to design and implement intervention programs, develop prognostic models to achieve better care outcomes for EPLHIV. This cohort would provide vital information for stakeholders in HIV prevention, care and treatment to understand the characteristics of EPLHIV.
Sections du résumé
BACKGROUND
BACKGROUND
The Nigerian HIV Geriatric Cohort (NHGC) is a longitudinal cohort setup to learn how elderly people living with HIV (EPLHIV) in Nigeria fare, despite not being prioritized by the national treatment program, and to deepen knowledge for their differentiated care and achieve better outcomes. In this paper, we describe data collected on sociodemographic and clinical data from EPLHIV from the inception of Nigeria's national HIV program to 2018.
METHODS
METHODS
Patient-level data spanning the period 2004 to 2018, obtained from comprehensive HIV treatment hospitals, that are supported by four major PEPFAR-implementing partners in Nigeria were used. These 4 entities collaborated as member organizations of the Nigeria Implementation Science Alliance. We defined elderly as those aged 50 years and above. From deidentified treatment records, demographic and clinical data of EPLHIV ≥50-year-old at ART initiation during the review period was extracted, merged into a single REDcap® database, and described using STATA 13.
RESULTS
RESULTS
A total of 101,652 EPLHIV were analysed. Women accounted for 53,608 (53%), 51,037 (71%) of EPLHIV identified as married and 33,446 (51%) unemployed. Median age was 57.1 years (IQR 52-60 years) with a median duration on ART treatment of 4.1 years (IQR 1.7-7.1 years). ART profile showed that 97,586 (96%) were on 1st-line and 66,125 (65%) were on TDF-based regimens. Median body mass index (BMI) was 22.2 kg/m
CONCLUSIONS
CONCLUSIONS
This cohort describes the clinical and non-clinical profile of EPLHIV in Nigeria. We are following up the cohort to design and implement intervention programs, develop prognostic models to achieve better care outcomes for EPLHIV. This cohort would provide vital information for stakeholders in HIV prevention, care and treatment to understand the characteristics of EPLHIV.
Identifiants
pubmed: 33243227
doi: 10.1186/s12889-020-09833-9
pii: 10.1186/s12889-020-09833-9
pmc: PMC7690164
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1797Références
J Clin Endocrinol Metab. 1999 Jun;84(6):1932-7
pubmed: 10372689
AIDS. 1999 Jul 9;13(10):F63-70
pubmed: 10416516
Geriatrics. 2005 Sep;60(9):26-30
pubmed: 16153142
AIDS. 2012 Jul 31;26 Suppl 1:S1-5
pubmed: 22713477
AIDS. 2012 Jul 31;26 Suppl 1:S19-30
pubmed: 22781175
PLoS One. 2018 Nov 29;13(11):e0207005
pubmed: 30496302
Arch Pathol Lab Med. 2009 Jan;133(1):78-82
pubmed: 19123741
Malawi Med J. 2010 Dec;22(4):101-3
pubmed: 21977829
Ageing Res Rev. 2004 Jan;3(1):31-54
pubmed: 15164725
Metabolism. 1991 Jun;40(6):651-6
pubmed: 1865829
Curr Infect Dis Rep. 2009 May;11(3):246-54
pubmed: 19366568
Curr HIV Res. 2015;13(4):268-78
pubmed: 25642849
Arch Intern Med. 2005 May 23;165(10):1179-84
pubmed: 15911733
Bull World Health Organ. 2010 Nov 1;88(11):847-53
pubmed: 21076566
Afr J Med Med Sci. 2007 Sep;36(3):267-72
pubmed: 18390067
Medicine (Baltimore). 2019 Apr;98(15):e15024
pubmed: 30985651